Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. 50 samples overall tested positive for the delta variant, 13 in the vaccine group and 37 in the placebo group, giving a vaccine efficacy against delta variant disease of 65·2% (33·1–83·0). The authors concluded that the BBV152 vaccine had an acceptable safety profile, with similar safety results to other inactivated SARS-CoV-2 vaccine candidates. 9 Rostad CAAnderson EJ Optimism and caution for an inactivated COVID-19 vaccine.

Source: New York Times November 11, 2021 19:09 UTC